Clinical trials: Non-Small Cell Lung Cancer Non-squamous
Non-Small Cell Lung Cancer, Brain Neoplasms
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated…
- Trial name
- NCT00312728
- Testing
- bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents
- Volunteers
- 115 people
- Sponsor
- Genentech, Inc.
Lung Cancer
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
Rationale: Advanced non-small-cell lung cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations (del19 or L858R) show an impressive progression-free survival between 9 and 14 months when treated with…
- Trial name
- BELIEF (NCT01562028)
- Testing
- Erlotinib, Bevacizumab
- Where
- 48 sites in France, Germany and 6 more
- Volunteers
- 109 people
- Sponsor
- ETOP IBCSG Partners Foundation
Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00323869
- Testing
- Bevacizumab, Gemcitabine, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Lung Neoplasms, Squamous Cell Lung Cancer
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
This phase II trial studies how well icotinib works in treating patients with completely resected stage IB NSCLC harboring EGFR mutation.
- Conditions
- Lung Neoplasms, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
- Trial name
- CORIN (NCT02264210)
- Testing
- Icotinib
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Sun Yat-sen University
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Non Small Cell Lung Cancer
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer.
- Trial name
- SQUIRE (NCT00981058)
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 182 sites in United States, Australia and 24 more
- Volunteers
- 1,093 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC…
- Conditions
- Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation
- Trial name
- NCT05275673
- Testing
- sapanisertib
- Where
- 14 sites in United States
- Volunteers
- 7 people
- Sponsor
- Faeth Therapeutics
Non-Small Cell Lung Cancer, Breast Cancer
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT02403271
- Testing
- Ibrutinib, Durvalumab
- Where
- 17 sites in United States
- Volunteers
- 124 people
- Sponsor
- Pharmacyclics LLC.
Lung Cancer
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.
- Trial name
- NCT01443078
- Testing
- pemetrexed, cisplatin, Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
This randomized phase III trial studies how well gefitinib works in treating patients with stage IB, II, or IIIA non-small cell lung cancer that was completely removed by surgery.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00049543
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 503 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
The purpose of this study was to evaluate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162 in advanced NSCLC patients carrying specific molecular alterations.
- Trial name
- NCT02276027
- Testing
- BYL719, INC280, LDK378
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00729612
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Greg Otterson
Non Squamous Non Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
This randomized phase II study will compare the efficacy and safety of the combination of carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated advanced non-squamous NSCLC.
- Trial name
- Spruce (NCT01829113)
- Testing
- OGX-427
- Where
- 16 sites in United States
- Volunteers
- 155 people
- Sponsor
- SCRI Development Innovations, LLC
Carcinoma, Non-Small-Cell Lung
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
Using a laboratory test (VeriStrat), patients with relapsed squamous cell lung cancer are assigned to two strata, VSG (VeriStrat Good) and VSP (VeriStrat Poor).
- Trial name
- EMPHASIS (NCT01652469)
- Testing
- Erlotinib, Docetaxel
- Where
- 32 sites in Austria, Belgium and 10 more
- Volunteers
- 81 people
- Sponsor
- ETOP IBCSG Partners Foundation
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of fibroblast growth factor receptor (FGFR) inhibitor AZD4547 when given with docetaxel and to see how well it works in treating patients with recurrent…
- Trial name
- NCT01824901
- Testing
- docetaxel, AZD4547
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00979212
- Testing
- panitumumab, carboplatin, paclitaxel
- Where
- 31 sites in United States
- Volunteers
- 71 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either…
- Trial name
- NCT02409342
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin
- Where
- 142 sites in United States, Brazil and 17 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
- Conditions
- Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer
- Trial name
- NCT01045421
- Testing
- MLN8237 (Alisertib)
- Where
- 2 sites in United States
- Volunteers
- 273 people
- Sponsor
- Millennium Pharmaceuticals, Inc.